81 FR 15188 - Schedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 Into Schedule I; Correction
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 81, Issue 55 (March 22, 2016)
Drug Enforcement Administration
Federal Register Volume 81, Issue 55 (March 22, 2016)
| Page Range | 15188-15190 | |
| FR Document | 2016-06474 |
[Federal Register Volume 81, Number 55 (Tuesday, March 22, 2016)] [Proposed Rules] [Pages 15188-15190] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-06474] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-417C] Schedules of Controlled Substances: Placement of UR-144, XLR11, and AKB48 Into Schedule I; Correction AGENCY: Drug Enforcement Administration, Department of Justice. [[Page 15189]] ACTION: Notice of proposed rulemaking; correction. ----------------------------------------------------------------------- SUMMARY: The Drug Enforcement Administration published a document in the Federal Register of May 14, 2015, concerning the proposal to place (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR- 144), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1- adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into schedule I of the Controlled Substances Act (CSA), specifically under cannabimimetic agents. This corrected notice of proposed rulemaking proposes to place such substances into schedule I of the CSA under hallucinogenic substances. DATES: Interested persons may file written comments on this correction to the initial proposal in accordance with 21 CFR 1308.43(g). The DEA is requesting comments on this change only and is not soliciting comments on other aspects of the May 14, 2015, notice of proposed rulemaking published at 80 FR 27611. Electronic comments must be submitted, and written comments must be postmarked, on or before April 21, 2016. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. ADDRESSES: To ensure proper handling of comments, please reference ``Docket No. DEA-417C'' on all correspondence, including any attachments. The Drug Enforcement Administration encourages that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the Web page or to attach a file for lengthier comments. Please go to http://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on Regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attn: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. FOR FURTHER INFORMATION CONTACT: Barbara J. Boockholdt, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812. SUPPLEMENTARY INFORMATION: Posting of Public Comments Please note that all comments received are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at http://www.regulations.gov. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase ``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your comment. You must also place all of the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted. If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. Comments containing personal identifying information and confidential business information identified as directed above will generally be made publicly available in redacted form. If a comment has so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to http://www.regulations.gov may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential. An electronic copy of this document is available at http://www.regulations.gov for easy reference. Legal Authority The DEA implements and enforces Titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the ``Controlled Substances Act'' and the ``Controlled Substances Import and Export Act,'' respectively, and are collectively referred to as the ``Controlled Substances Act'' or the ``CSA'' for the purposes of this action. 21 U.S.C. 801-971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Under the CSA, each controlled substance is classified into one of five schedules based upon its potential for abuse, its currently accepted medical use in treatment in the United States, and the degree of dependence the substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c) and the current list of scheduled substances is published at 21 CFR part 1308. 21 U.S.C. 812(a). Pursuant to 21 U.S.C. 811(a)(1), the Attorney General may, by rule, ``add to such a schedule or transfer between such schedules any drug or other substance if he * * * finds that such drug or other substance has a potential for abuse, and * * * makes with respect to such drug or other substance the findings prescribed by subsection (b) of section 812 of this title for the schedule in which such drug is to be placed * * *.'' The Attorney General has delegated scheduling authority under 21 U.S.C. 811 to the Administrator of the DEA. 28 CFR 0.100. The CSA provides that proceedings for the issuance, amendment, or repeal of the scheduling of any drug or other substance may be initiated by the Attorney General (1) on her own motion; (2) at the request of the Secretary of the Department of Health [[Page 15190]] and Human Services (HHS),\1\ or (3) on the petition of any interested party. 21 U.S.C. 811(a). This proposed action (80 FR 27611, May 14, 2015) is supported by a recommendation from the Assistant Secretary of the HHS and an evaluation of all other relevant data by the DEA. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions of schedule I controlled substances on any person who handles, or proposes to handle, UR-144, XLR11, or AKB48. --------------------------------------------------------------------------- \1\ As discussed in a memorandum of understanding entered into by the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), the FDA acts as the lead agency within the HHS in carrying out the Secretary's scheduling responsibilities under the CSA, with the concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. The Secretary of the HHS has delegated to the Assistant Secretary for Health of the HHS the authority to make domestic drug scheduling recommendations. 58 FR 35460, July 1, 1993. --------------------------------------------------------------------------- Background UR-144, XLR11, and AKB48 are currently subject to schedule I controls on a temporary basis, pursuant to 21 U.S.C. 811(h). 80 FR 27854, May 15, 2015. On May 14, 2015, the Administrator of the DEA published a notice of proposed rulemaking (NPRM) to permanently schedule (1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11), and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) into schedule I pursuant to the CSA. 80 FR 27611. In the NPRM, the DEA inadvertently proposed the addition of these substances in schedule I under 21 CFR 1308.11(g), cannabimimetic agents, by adding paragraphs (g)(16) through (18). These substances should have been proposed to be added in schedule I under 21 CFR 1308.11(d), hallucinogenic substances. This rulemaking therefore corrects the NPRM by proposing the placement of these substances in 21 CFR 1308.11(d) by adding paragraphs (d)(48) through (50). Because the DEA is proposing to classify these substances as schedule I hallucinogenic substances, then by operation of 21 U.S.C. 802(14), this classification will include any optical, positional, or geometric isomers. Interested persons may file written comments on this change in accordance with 21 CFR 1308.43(g). The DEA is requesting comments on this change only and is not soliciting comments on other aspects of the May 14, 2015, NPRM. The DEA previously had provided an opportunity for comments on other aspects of the NPRM on May 14, 2015, through June 15, 2015. Regulatory Analyses This correction has no effect on the regulatory analyses statements that were published with the notice of proposed rulemaking published in the Federal Register on May 14, 2015, at 80 FR 27611. Correction In proposed rule FR Doc. 2015-11762, beginning on page 27611 in the issue of May 14, 2015, make the following corrections. 0 1. On page 27616 in the 3rd column, correct amendatory instruction 2.a. to read as follows: ``Adding paragraphs (d)(65) through (67); and''. 0 2. On page 27616 in the 3rd column, correct Sec. 1308.11 Schedule I regulatory text to read as follows: Sec. 1308.11 Schedule I. * * * * * (d) * * * (65) (1-pentyl-1H-indol-3-yl)(2,2,3,3- (7144) tetramethylcyclopropyl)methanone (UR-144).............. (66) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- (7011) tetramethylcyclopropyl) methanone (5-fluoro-UR-144, XLR11)................................................. (67) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (7048) (APINACA, AKB48)....................................... * * * * * Dated: March 16, 2016. Chuck Rosenberg, Acting Administrator. [FR Doc. 2016-06474 Filed 3-21-16; 8:45 am] BILLING CODE 4410-09-P
![15188 Federal Register / Vol. 81, No. 55 / Tuesday, March 22, 2016 / Proposed Rules
Latex Medical Gloves (Surgeons’ and 21 CFR Part 895 PART 895—BANNED DEVICES
Examination) Powdered Latex Medical
Gloves (Surgeons’ and Examination),’’ Administrative practice and ■ 6. The authority citation for 21 CFR
1998, MDA: London. procedure, Labeling, Medical devices. part 895 continues to read as follows:
66. Latza, U., F. Haamann, and X. Baur,
‘‘Effectiveness of a Nationwide Therefore, under the Federal Food, Authority: 21 U.S.C. 352, 360f, 360h, 360i,
Interdisciplinary Preventive Programme Drug, and Cosmetic Act and under 371.
for Latex Allergy,’’ International authority delegated to the Commissioner ■ 7. Add § 895.102 to subpart B to read
Archives of Occupational and of Food and Drugs, it is proposed that as follows:
Environmental Health, 78(5):394–402, 21 CFR parts 878, 880, and 895 be
2005, available at: http:// amended as follows: § 895.102 Powdered surgeon’s glove.
link.springer.com/article/ A powdered surgeon’s glove is a
10.1007%2Fs00420-004-0594-2. PART 878—GENERAL AND PLASTIC device made of natural rubber latex or
67. U.S. Department of Labor, OSHA, SURGERY DEVICES
Potential for Sensitization and Possible synthetic latex, intended to be worn by
Allergic Reaction To Natural Rubber operating room personnel to protect a
■ 1. The authority citation for 21 CFR surgical wound from contamination. A
Latex Gloves and Other Natural Rubber
Products, 2008. Available at: https:// part 878 continues to read as follows: powdered surgeon’s glove incorporates
www.osha.gov/dts/shib/ Authority: 21 U.S.C. 351, 360, 360c, 360e, powder for purposes other than
shib012808.html. 360j, 360l, 371. manufacturing.
68. Bolyard, E.A., O.C. Tablan, W.W. ■ 8. Add § 895.103 to subpart B to read
Williams, et al., ‘‘Guideline for Infection ■ 2. Amend § 878.4460 by revising the
as follows:
Control in Healthcare Personnel, 1998. heading and paragraph (a) to read as
Hospital Infection Control Practices follows: § 895.103 Powdered patient examination
Advisory Committee,’’ Infection Control glove.
and Hospital Epidemiology, 19(6):407– § 878.4460 Non-powdered surgeon’s
glove. A powdered patient examination
463, 1998.
69. Blumenstock, J.S., E. Bresnitz, and K. glove is a disposable device made of
(a) Identification. A non-powdered natural rubber latex or synthetic latex,
O’Leary, Guidelines Management of
surgeon’s glove is a device made of intended for medical purposes, that is
Natural Rubber Latex Allergy; Selecting
the Right Glove for the Right Task in natural rubber latex or synthetic latex, worn on the examiner’s hand or finger
Healthcare Facilities, New Jersey intended to be worn by operating room to prevent contamination between
Department of Health and Senior personnel to protect a surgical wound patient and examiner. A powdered
Services, ed. B. Gerwel, 2000. from contamination. A non-powdered patient examination glove incorporates
70. United Kingdom National Health Service, surgeon’s glove does not incorporate powder for purposes other than
N.P., Royal College of Physicians, powder for purposes other than manufacturing.
Faculty of Occupational Medicine, manufacturing. The final finished glove ■ 9. Add § 895.104 to subpart B to read
‘‘Latex Allergy: Occupational Aspects of includes only residual powder from
Management. A National Guideline,’’ as follows:
manufacturing.
2008, London: RCP.
* * * * * § 895.104 Absorbable powder for
71. Olmsted, R., ‘‘APIC response to FDA
lubricating a surgeon’s glove.
Docket # FDA–2011–N–0027,’’ available
at www.regulations.gov, 2011. § 878.4480 [Removed] Absorbable powder for lubricating a
72. ‘‘Finding of No Significant Impact ■ 3. Remove § 878.4480. surgeon’s glove is a powder made from
(FONSI) and Environmental Analysis for cornstarch that meets the specifications
Banned Devices; Proposal to Ban PART 880—GENERAL HOSPITAL AND for absorbable powder in the United
Powdered Surgeon’s Gloves, Powdered PERSONAL USE DEVICES States Pharmacopeia (U.S.P.) and that is
Patient Examination Gloves, and intended to be used to lubricate the
Absorbable Powder for Lubricating a ■ 4. The authority citation for 21 CFR surgeon’s hand before putting on a
Surgeon’s Glove.’’ part 880 continues to read as follows:
73. Korniewicz, D.M., N. Chookaew, M. El- surgeon’s glove. The device is
Masri, et al., ‘‘Conversion to Low- Authority: 21 U.S.C. 351, 360, 360c, 360e, absorbable through biological
Protein, Powder-Free Surgical Gloves: Is 360j, 371. degradation.
It Worth the Cost?’’ American Dated: March 16, 2016.
Association of Occupational Health ■ 5. Amend § 880.6250 by revising the
heading and paragraph (a) to read as Leslie Kux,
Nurses Journal, 53(9):388–393, 2005.
74. Ranta, P.M. and D.R. Ownby, ‘‘A Review follows: Associate Commissioner for Policy.
of Natural-Rubber Latex Allergy in [FR Doc. 2016–06360 Filed 3–21–16; 8:45 am]
Health Care Workers,’’ Clinical § 880.6250 Non-powdered patient
BILLING CODE 4164–01–P
Infectious Diseases, 38(2):252–256, 2004. examination glove.
75. ‘‘Preliminary Regulatory Impact Analysis, (a) Identification. A non-powdered
Initial Regulatory Flexibility Analysis, patient examination glove is a
and Unfunded Mandates Reform Act DEPARTMENT OF JUSTICE
disposable device made of either natural
Analysis for Banned Devices; Proposal to
rubber latex or synthetic latex, intended Drug Enforcement Administration
Ban Powdered Surgeon’s Gloves,
for medical purposes, that is worn on
asabaliauskas on DSK3SPTVN1PROD with PROPOSALS
Powdered Patient Examination Gloves,
and Absorbable Powder for Lubricating a the examiner’s hand or finger to prevent 21 CFR Part 1308
Surgeon’s Glove,’’ available at http:// contamination between patient and
www.fda.gov/AboutFDA/ examiner. A non-powdered patient [Docket No. DEA–417C]
ReportsManualsForms/Reports/ examination glove does not incorporate
EconomicAnalyses/default.htm. powder for purposes other than Schedules of Controlled Substances:
manufacturing. The final finished glove Placement of UR–144, XLR11, and
List of Subjects AKB48 Into Schedule I; Correction
includes only residual powder from
21 CFR Parts 878 and 880 manufacturing. AGENCY:Drug Enforcement
Medical devices. * * * * * Administration, Department of Justice.
VerDate Sep<11>2014 17:38 Mar 21, 2016 Jkt 238001 PO 00000 Frm 00018 Fmt 4702 Sfmt 4702 E:\FR\FM\22MRP1.SGM 22MRP1](https://thefederalregister.org/doc/81_FR_15243/page/1.svg)
methanone (5- Barbara J. Boockholdt, Office of of 1970, as amended. 21 U.S.C. 801–971.
fluoro-UR-144, XLR11), and N-(1- Diversion Control, Drug Enforcement Titles II and III are referred to as the
adamantyl)-1-pentyl-1H-indazole-3- Administration; Mailing Address: 8701 ‘‘Controlled Substances Act’’ and the
carboxamide (APINACA, AKB48) Morrissette Drive, Springfield, Virginia ‘‘Controlled Substances Import and
including their salts, isomers, and salts 22152; Telephone: (202) 598–6812. Export Act,’’ respectively, and are
of isomers whenever the existence of SUPPLEMENTARY INFORMATION: collectively referred to as the
such salts, isomers, and salts of isomers Posting of Public Comments ‘‘Controlled Substances Act’’ or the
is possible, into schedule I of the ‘‘CSA’’ for the purposes of this action.
Controlled Substances Act (CSA), Please note that all comments 21 U.S.C. 801–971. The DEA publishes
specifically under cannabimimetic received are considered part of the the implementing regulations for these
agents. This corrected notice of public record. They will, unless statutes in title 21 of the Code of Federal
proposed rulemaking proposes to place reasonable cause is given, be made Regulations (CFR), chapter II. The CSA
such substances into schedule I of the available by the Drug Enforcement and its implementing regulations are
CSA under hallucinogenic substances. Administration (DEA) for public designed to prevent, detect, and
inspection online at http:// eliminate the diversion of controlled
DATES: Interested persons may file www.regulations.gov. Such information substances and listed chemicals into the
written comments on this correction to includes personal identifying illicit market while providing for the
the initial proposal in accordance with information (such as your name, legitimate medical, scientific, research,
21 CFR 1308.43(g). The DEA is address, etc.) voluntarily submitted by and industrial needs of the United
requesting comments on this change the commenter. The Freedom of States. Controlled substances have the
only and is not soliciting comments on Information Act (FOIA) applies to all potential for abuse and dependence and
other aspects of the May 14, 2015, comments received. If you want to are controlled to protect the public
notice of proposed rulemaking submit personal identifying information health and safety.
published at 80 FR 27611. Electronic (such as your name, address, etc.) as Under the CSA, each controlled
comments must be submitted, and part of your comment, but do not want substance is classified into one of five
written comments must be postmarked, it to be made publicly available, you schedules based upon its potential for
on or before April 21, 2016. must include the phrase ‘‘PERSONAL abuse, its currently accepted medical
Commenters should be aware that the IDENTIFYING INFORMATION’’ in the use in treatment in the United States,
electronic Federal Docket Management first paragraph of your comment. You and the degree of dependence the
System will not accept comments after must also place all of the personal substance may cause. 21 U.S.C. 812. The
11:59 p.m. Eastern Time on the last day identifying information you do not want initial schedules of controlled
of the comment period. made publicly available in the first substances established by Congress are
ADDRESSES: To ensure proper handling paragraph of your comment and identify found at 21 U.S.C. 812(c) and the
of comments, please reference ‘‘Docket what information you want redacted. current list of scheduled substances is
No. DEA–417C’’ on all correspondence, If you want to submit confidential published at 21 CFR part 1308. 21
including any attachments. The Drug business information as part of your U.S.C. 812(a).
Enforcement Administration encourages comment, but do not want it to be made Pursuant to 21 U.S.C. 811(a)(1), the
that all comments be submitted publicly available, you must include the Attorney General may, by rule, ‘‘add to
electronically through the Federal phrase ‘‘CONFIDENTIAL BUSINESS such a schedule or transfer between
eRulemaking Portal, which provides the INFORMATION’’ in the first paragraph such schedules any drug or other
ability to type short comments directly of your comment. You must also substance if he * * * finds that such
into the comment field on the Web page prominently identify confidential drug or other substance has a potential
or to attach a file for lengthier business information to be redacted for abuse, and * * * makes with respect
comments. Please go to http:// within the comment. to such drug or other substance the
www.regulations.gov and follow the Comments containing personal findings prescribed by subsection (b) of
online instructions at that site for identifying information and confidential section 812 of this title for the schedule
submitting comments. Upon completion business information identified as in which such drug is to be placed
of your submission you will receive a directed above will generally be made * * *.’’ The Attorney General has
Comment Tracking Number for your publicly available in redacted form. If a delegated scheduling authority under 21
asabaliauskas on DSK3SPTVN1PROD with PROPOSALS
comment. Please be aware that comment has so much confidential U.S.C. 811 to the Administrator of the
submitted comments are not business information or personal DEA. 28 CFR 0.100.
instantaneously available for public identifying information that it cannot be The CSA provides that proceedings
view on Regulations.gov. If you have effectively redacted, all or part of that for the issuance, amendment, or repeal
received a Comment Tracking Number, comment may not be made publicly of the scheduling of any drug or other
your comment has been successfully available. Comments posted to http:// substance may be initiated by the
submitted and there is no need to www.regulations.gov may include any Attorney General (1) on her own
resubmit the same comment. Paper personal identifying information (such motion; (2) at the request of the
comments that duplicate the electronic as name, address, and phone number) Secretary of the Department of Health
VerDate Sep<11>2014 17:36 Mar 21, 2016 Jkt 238001 PO 00000 Frm 00019 Fmt 4702 Sfmt 4702 E:\FR\FM\22MRP1.SGM 22MRP1](https://thefederalregister.org/doc/81_FR_15243/page/2.svg)
methanone (5- only and is not soliciting comments on * * * * *
fluoro-UR-144, XLR11), and N-(1- other aspects of the May 14, 2015, (d) * * *
(65) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ...................................................................... (7144)
(66) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (5-fluoro-UR-144, XLR11) ........................ (7011)
(67) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48) .......................................................................... (7048)
* * * * * restoration, or coastal wetlands your comments and include your name
Dated: March 16, 2016. restoration projects by Federal, State, or and return address.
local government agencies, or use in • Federal eRulemaking Portal: http://
Chuck Rosenberg,
construction projects authorized by or www.regulations.gov. Under the tab
Acting Administrator. ‘‘More Search Options,’’ click
funded in whole or in part by the
[FR Doc. 2016–06474 Filed 3–21–16; 8:45 am] ‘‘Advanced Docket Search,’’ then select
Federal Government. The proposed rule
BILLING CODE 4410–09–P describes the negotiated noncompetitive ‘‘Bureau of Ocean Energy Management’’
agreement process for qualifying from the agency drop-down menu, then
projects and codifies new and existing click the submit button. In the Docket ID
DEPARTMENT OF THE INTERIOR procedures. column, select BOEM–2010–0041 to
submit public comments and to view
Bureau of Ocean Energy Management DATES: Submit comments by May 23,
supporting and related materials
2016. The Bureau of Ocean Energy
available for this rulemaking.
30 CFR Part 583 Management (BOEM) may not fully
Information on using Regulations.gov,
consider comments received after this
RIN 1010–AD90 including instructions for accessing
date. Submit comments to the Office of
documents, submitting comments, and
[Docket ID: BOEM–2010–0041] Management and Budget (OMB) on the
viewing the docket after the close of the
information collection (IC) burden in
comment period, is available through
Negotiated Noncompetitive Leasing for this proposed rule by April 21, 2016.
the site’s ‘‘User Tips’’ link. BOEM will
the Use of Sand, Gravel, and Shell This does not affect the deadline for the
post comments on www.regulations.gov.
Resources on the Outer Continental public to comment to BOEM on the • Mail or hand-carry comments to the
Shelf proposed regulation. U.S. Department of the Interior; Bureau
AGENCY: Bureau of Ocean Energy ADDRESSES : You may submit comments of Ocean Energy Management; Attn:
Management, Interior. on the rulemaking by any of the Office of Policy, Regulation and
ACTION: Proposed rule. following methods. Please use the Analysis, 45600 Woodland Road, VAM–
asabaliauskas on DSK3SPTVN1PROD with PROPOSALS
Regulation Identifier Number (RIN) BOEM DIR, Sterling, Virginia 20166.
SUMMARY: This rule proposes regulations 1010–AD90 as an identifier in your • Send comments on the IC in this
to address the use of Outer Continental comment. Please reference ‘‘Outer proposed rule to: Interior Desk Officer
Shelf (OCS) sand, gravel and shell Continental Shelf Marine Sand, Gravel 1010–AD90, Office of Management and
resources for shore protection, beach and Shell Resources, 1010–AD90’’ in Budget; 202–395–5806 (fax); email:
1 As discussed in a memorandum of within the HHS in carrying out the Secretary’s Assistant Secretary for Health of the HHS the
understanding entered into by the Food and Drug scheduling responsibilities under the CSA, with the authority to make domestic drug scheduling
Administration (FDA) and the National Institute on concurrence of NIDA. 50 FR 9518, Mar. 8, 1985. recommendations. 58 FR 35460, July 1, 1993.
Drug Abuse (NIDA), the FDA acts as the lead agency The Secretary of the HHS has delegated to the
VerDate Sep<11>2014 17:36 Mar 21, 2016 Jkt 238001 PO 00000 Frm 00020 Fmt 4702 Sfmt 4702 E:\FR\FM\22MRP1.SGM 22MRP1](https://thefederalregister.org/doc/81_FR_15243/page/3.svg)
Document Created: 2018-02-02 15:15:50
Document Modified: 2018-02-02 15:15:50
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Proposed Rules | |
| Action | Notice of proposed rulemaking; correction. | |
| Dates | Interested persons may file written comments on this correction to the initial proposal in accordance with 21 CFR 1308.43(g). The DEA is requesting comments on this change only and is not soliciting comments on other aspects of the May 14, 2015, notice of proposed rulemaking published at 80 FR 27611. Electronic comments must be submitted, and written comments must be postmarked, on or before April 21, 2016. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. | |
| Contact | Barbara J. Boockholdt, Office of | |
| FR Citation | 81 FR 15188 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR